What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trials ARCADIA 1 and ARCADIA 2 demonstrated that nemolizumab significantly improved EASI 75 response compared to placebo, with results showing 43.5% and 42.1% response rates respectively at week 16. This indicates a clear clinical advantage over standard care, although indirect comparisons with other biological treatments showed no statistically significant differences, suggesting that while effective, nemolizumab may not be superior to all comparators.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for nemolizumab are within the acceptable range for Healthcare resources, particularly when compared to biological medicines. However, it is noted that it is not cost-effective compared to JAK inhibitors, indicating a marginally defensible position depending on the comparator.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that nemolizumab leads to improvements in quality of life as measured by the Dermatology Life Quality Index (DLQI), with a required reduction of 4 points to define an adequate response. This suggests moderate gains in HRQoL, although specific effect sizes were not detailed.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Nemolizumab has a very good safety profile with mostly mild to moderate adverse events reported. The committee noted that it may avoid some troubling side effects associated with current treatments, indicating a favorable tolerability compared to existing options.
Was the drug compared against what payers expect? — Comparator Selection
The clinical trials included relevant comparators such as JAK inhibitors and other biological medicines. The committee acknowledged that while the initial submission did not include all relevant comparators, updates included these treatments, aligning with current clinical practice.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a representative population of individuals aged 12 years and older, with a focus on those who had not responded to systemic treatments. This suggests a moderate level of generalizability to the intended patient population.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nemolizumab can be integrated into existing treatment pathways with minimal adjustments, as it is used in conjunction with topical treatments. The committee noted that it fits well within the current management strategies for atopic dermatitis.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of nemolizumab is manageable, particularly given its cost-effectiveness compared to biological alternatives. The committee concluded that it would not impose an unsustainable burden on the Healthcare.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by multiple phase 3 trials with low bias risk. The committee noted that the trials were well-designed and provided robust data, although some uncertainties remained regarding indirect comparisons.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the indirect comparisons and the economic model, the committee noted that these were manageable and did not significantly undermine the overall conclusions about the treatment’s value.
